Johnson & Johnson Receives FDA Approval For IMAAVY (nipocalimab-aahu)
Reuters
昨天
April 30 (Reuters) - Johnson & Johnson :: *JOHNSON & JOHNSON RECEIVES FDA APPROVAL FOR IMAAVY™ (NIPOCALIMAB-AAHU), A NEW FCRN BLOCKER OFFERING LONG-LASTING DISEASE CONTROL IN THE BROADEST POPULATION OF PEOPLE LIVING WITH GENERALIZED MYASTHENIA GRAVIS $(GMG.AU)$